Kyverna Therapeutics, Inc. KYTX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Kyverna Therapeutics, Inc.’s reported figures.
The official record: Kyverna Therapeutics, Inc.’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- Kyverna Therapeutics, Inc. (KYTX) reported free cash flow of -$33.53M in Q4 2025.
- How has Kyverna Therapeutics, Inc.'s free cash flow changed year-over-year?
- Kyverna Therapeutics, Inc.'s free cash flow increased by 10.8% year-over-year, from -$37.59M to -$33.53M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s free cash flow?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s free cash flow has grown at a 70.3% compound annual growth rate (CAGR), from -$53.03M to -$153.72M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.